What is Addyi’s (flibanserin) approval status in 2026 for postmenopausal people?
Addyi (flibanserin) is approved in the U.S. for a specific indication that applies to premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). It is not approved for postmenopausal women.
That means, for a request like “Addyi flibanserin postmenopausal approval status 2026,” the key point is that Addyi does not have a postmenopausal indication in the provided information available here.
Can Addyi be prescribed off-label for postmenopausal HSDD?
Even when a drug is approved for one population, clinicians sometimes prescribe it off-label to other groups based on emerging evidence or individual circumstances. However, whether an off-label use is reasonable depends on clinical evidence and safety data for that population, and it’s separate from the drug’s formal regulatory approval status.
Why would someone look for “postmenopausal approval” specifically?
Searchers often want to know whether:
- the FDA has expanded Addyi’s label beyond premenopausal women, or
- other regulators (or later FDA label changes) have added a postmenopausal indication.
If you want, tell me which country you mean (U.S., EU, UK, Canada, etc.), and I can narrow the answer to that regulator’s current label status for 2026.